ELYM insider filings
Eliem Therapeutics, Inc. — 44 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-09-20. Screen ELYM transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ELYM between 2026-07-26 and 2026-10-24. The table below lists the most recent filings on record.
Recent insider filings — Eliem Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-09-20 | 4 | Pimblett Emily — CHIEF ACCOUNTING OFFICER | Option exercise (M): 5,000 · Sale (S): 1,182 @ $8.18 · Sale (S): 9 @ $8.06 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-08-26 | 4 | Kaplan Brett — Chief Operating Officer | Grant/award (A): 465,000 (derivative) @ $0 · Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2024-07-23 | 4 | Morisset Valerie — EVP, R&D AND CSO | Sale (S): 10,201 @ $7.09 · Sale (S): 50,000 @ $7.24 · Sale (S): 39,005 @ $8.07 · Sale (S): 30,000 @ $7.98 | EDGAR |
| 2024-07-19 | 4 | Morisset Valerie — EVP, R&D AND CSO | Sale (S): 3,207 @ $6.91 · Sale (S): 38,576 @ $6.93 | EDGAR |
| 2024-07-17 | 4 | Morisset Valerie — EVP, R&D AND CSO | Sale (S): 50,000 @ $7.13 | EDGAR |
| 2024-07-16 | 4 | Morisset Valerie — EVP, R&D AND CSO | Sale (S): 50,000 @ $7.07 · Sale (S): 42,377 @ $7.01 | EDGAR |
| 2024-07-11 | 4 | Morisset Valerie — EVP, R&D AND CSO | Sale (S): 5,931 @ $6.66 · Sale (S): 50,000 @ $6.83 · Sale (S): 50,000 @ $7.11 | EDGAR |
| 2024-07-09 | 4 | Morisset Valerie — EVP, R&D AND CSO | Sale (S): 12,342 @ $7.06 | EDGAR |
| 2024-07-03 | 4 | Morisset Valerie — EVP, R&D AND CSO | Option exercise (M): 7,649 @ $0.00 · Sale (S): 50,000 @ $6.76 · Option exercise (M): 7,649 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director RA Capital Nexus Fund II, L.P. — Director RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 973,000 · Grant/award (A): 2,479,872 · Grant/award (A): 1,807,000 · Purchase (P): 11,949,171 @ $3.84 · Purchase (P): 1,059,375 @ $3.84 | EDGAR |
| 2024-06-28 | 4 | Levin Andrew David — Executive Chairman, Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Rosenberg Adam Joseph — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Dunn Judith — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Tate Simon — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Ratcliffe Liam — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Thomas Stephen Basil — Director | Grant/award (A): 103,907 · Grant/award (A): 100,375 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Brennan Aoife — President and CEO, Director | Grant/award (A): 550,000 (derivative) @ $0 · Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Pimblett Emily — CHIEF ACCOUNTING OFFICER | Option exercise (M): 5,000 · Sale (S): 1,245 @ $7.21 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-04-08 | 4 | Morisset Valerie — EVP, R&D AND CSO | Option exercise (M): 17,847 @ $0.00 · Option exercise (M): 17,847 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | Pimblett Emily — CHIEF ACCOUNTING OFFICER | Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Morisset Valerie — EVP, R&D AND CSO | Option exercise (M): 5,431 @ $0.00 · Option exercise (M): 15,297 @ $0.00 · Option exercise (M): 5,431 (derivative) @ $0 · Option exercise (M): 15,297 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Tate Simon — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Dunn Judith — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Rosenberg Adam Joseph — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Levin Andrew David — Executive Chairman, Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Ratcliffe Liam — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director, 10% owner Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-03-14 | 4 | Morisset Valerie — EVP, R&D and CSO | Option exercise (M): 255,219 @ $0.00 · Option exercise (M): 61,191 @ $0.00 · Option exercise (M): 255,219 (derivative) @ $0 · Option exercise (M): 61,191 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | Morisset Valerie — EVP, R&D and CSO | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | Lavelle Erin — COO & CFO | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | Bucher James B — EVP and General Counsel | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | Azelby Robert — President & CEO, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | Tate Simon — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | Rosenberg Adam Joseph — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | Levin Andrew David — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | Dunn Judith — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | Ratcliffe Liam — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund, L.P. — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director, 10% owner Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-06-01 | 4 | PATTERSON LEONE D — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Morisset Valerie — EVP, R&D and CSO | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Lavelle Erin — COO & CFO | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Bucher James B — EVP and General Counsel | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Azelby Robert — President & CEO, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Eliem Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-23 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ELYM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs